---
title: "Weekly Recap | SXTC.US -5.31%, a week of fierce post-earnings swings"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296671045.md"
description: "China SXT Pharmaceuticals (SXTC) closed the week at $4.10, down 5.31%, while the S&P 500 fell 1.43%, leaving the stock trailing by roughly 3.88 percentage points. The trading week was exceptionally volatile with a 51.59% swing between the high and low. Monday opened at $3.78 and drifted to a close of $3.75. Tuesday saw a dramatic surge, with the stock spiking to an intraday high of $5.55 before settling at $5.13. Wednesday gave back some ground, closing at $4.54."
datetime: "2026-08-22T05:48:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296671045.md)
  - [en](https://longbridge.com/en/news/296671045.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296671045.md)
generator: "portal-rs"
---

# Weekly Recap | SXTC.US -5.31%, a week of fierce post-earnings swings

## The Week

China SXT Pharmaceuticals (SXTC) closed the week at $4.10, down 5.31%, while the S&P 500 fell 1.43%, leaving the stock trailing by roughly 3.88 percentage points. The trading week was exceptionally volatile with a 51.59% swing between the high and low. Monday opened at $3.78 and drifted to a close of $3.75. Tuesday saw a dramatic surge, with the stock spiking to an intraday high of $5.55 before settling at $5.13. Wednesday gave back some ground, closing at $4.54. Thursday pulled back sharply to $3.63. Friday rebounded to $4.10. Daily volume averaged 3.48m shares, roughly 29 times the 60-day median, signalling intense activity throughout the week.

## Key Events

The week centred on a fierce reaction to the company’s second-quarter results. On Tuesday, healthcare sector momentum and strong earnings propelled the stock up as much as 43% intraday, hitting the week’s high of $5.55 before paring some gains to close roughly 19% higher. The after-hours session added another 4%, suggesting the positive earnings reception carried over. Wednesday opened with a sharp intraday reversal, dropping more than 7% at one point, as short-term profit-taking kicked in. By Friday’s pre-market, the stock rallied another 17.63%, and during the regular session it rose 12.39% on elevated volume, with market commentary pointing to speculative churn rather than a fresh catalyst.

## The Week Ahead

Tuesday brings a heavy slate of U.S. macro data: FHFA house prices, the Case-Shiller 20-city index, the Richmond Fed composite index, consumer confidence, and new home sales. The consumer confidence reading is forecast at 90.1, slightly below the prior 90.8, while housing data will offer fresh clues on the economy’s temperature. For SXTC, the key question is whether the stock can hold above the $4 level after the week’s wild swings and absorb the exceptionally high turnover triggered by the earnings news.

## In Short

SXTC delivered a week of extreme swings, fuelled by a strong earnings report, yet still closed lower — a sign of deep disagreement between buyers and sellers. The latest session’s fund flow shows a modest net inflow from large and medium orders, with retail money roughly neutral, painting no clear directional picture. Valuation metrics remain depressed: a negative price-to-earnings ratio and a price-to-book of just 0.07x, reflecting the market’s low pricing of its assets and earnings power. How next week’s macro data and broader sentiment evolve will likely determine whether the stock can break out of its near-term choppy pattern.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [SXTC.US](https://longbridge.com/en/quote/SXTC.US.md)

## Related News & Research

- [Will Lululemon Stock (LULU) Rise or Fall after Earnings Today?](https://longbridge.com/en/news/297924323.md)
- [Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying](https://longbridge.com/en/news/297940670.md)
- [Weight Watchers to join Morgan Stanley Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297910349.md)
- [Ultragenyx unit Amlogenyx presents at Wells Fargo Healthcare Conference Sept. 8](https://longbridge.com/en/news/297782170.md)
- [Xenon Pharma to Present at Wells Fargo Healthcare Conference](https://longbridge.com/en/news/297952103.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**